Related Experiment Video

Updated: May 24, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Denosumab for treatment of breast cancer bone metastases and beyond

Julie R Nangia1, Joseph D Ma, Christine M Nguyen

  • 1Baylor College of Medicine, Houston, TX 77030, USA.

Expert Opinion on Biological Therapy
|February 22, 2012
PubMed
Abstract

Insights

Denosumab is an effective treatment for bone metastases in breast cancer patients, offering an alternative to bisphosphonates with similar safety profiles. Further research is needed to define its optimal use and long-term efficacy.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • Bone metastases are a common and severe complication in 70-85% of metastatic breast cancer patients.
  • Current treatments include bisphosphonates, but denosumab offers an alternative therapy.
  • Denosumab targets the RANKL-RANK pathway, crucial in bone remodeling and metastasis.

Purpose of the Study:

  • To review denosumab's role in treating breast cancer bone metastases.
  • To discuss denosumab's pharmacokinetics, pharmacodynamics, efficacy, safety, and tolerability.
  • To explore the RANKL-RANK pathway's involvement in both bone and non-bone related mechanisms.

Main Methods:

  • Comprehensive review of clinical studies on denosumab.
  • Analysis of denosumab's pharmacokinetic and pharmacodynamic properties.
  • Evaluation of safety and tolerability data compared to bisphosphonates.

Main Results:

  • Denosumab demonstrates efficacy in treating breast cancer bone metastases.
  • Adverse event rates for denosumab are comparable to bisphosphonates.
  • Preclinical data suggest the RANKL-RANK pathway's role in mammary gland development and tumorigenesis.

Conclusions:

  • Denosumab is an efficacious option for breast cancer bone metastases with a similar safety profile to bisphosphonates.
  • Optimal duration of denosumab therapy and its definitive place in treatment remain to be established.
  • Further clinical investigation is required to address unanswered questions regarding denosumab's use.

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...